company background image
IRLA

IRLAB Therapeutics OM:IRLAB A Stock Report

Last Price

kr33.35

Market Cap

kr1.8b

7D

-1.8%

1Y

-45.8%

Updated

15 Aug, 2022

Data

Company Financials +
IRLAB A fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance3/6
Financial Health6/6
Dividends0/6

IRLAB A Stock Overview

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease.

IRLAB Therapeutics AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IRLAB Therapeutics
Historical stock prices
Current Share Pricekr33.35
52 Week Highkr63.00
52 Week Lowkr28.55
Beta0.47
1 Month Change-6.32%
3 Month Change-7.75%
1 Year Change-45.77%
3 Year Change-19.93%
5 Year Change19.96%
Change since IPO182.63%

Recent News & Updates

May 19
We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

Shareholders appeared to be happy with IRLAB Therapeutics AB (publ)'s ( STO:IRLAB A ) solid earnings report last week...

Shareholder Returns

IRLAB ASE PharmaceuticalsSE Market
7D-1.8%4.2%2.3%
1Y-45.8%-18.1%-21.8%

Return vs Industry: IRLAB A underperformed the Swedish Pharmaceuticals industry which returned -18.1% over the past year.

Return vs Market: IRLAB A underperformed the Swedish Market which returned -21.8% over the past year.

Price Volatility

Is IRLAB A's price volatile compared to industry and market?
IRLAB A volatility
IRLAB A Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement7.8%
Market Average Movement7.2%
10% most volatile stocks in SE Market12.6%
10% least volatile stocks in SE Market4.5%

Stable Share Price: IRLAB A is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: IRLAB A's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201324Richard Godfreyhttps://www.irlab.se

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases.

IRLAB Therapeutics AB (publ) Fundamentals Summary

How do IRLAB Therapeutics's earnings and revenue compare to its market cap?
IRLAB A fundamental statistics
Market Capkr1.76b
Earnings (TTM)kr42.65m
Revenue (TTM)kr216.91m

40.6x

P/E Ratio

8.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IRLAB A income statement (TTM)
Revenuekr216.91m
Cost of Revenuekr95.73m
Gross Profitkr121.18m
Other Expenseskr78.53m
Earningskr42.65m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 24, 2022

Earnings per share (EPS)0.82
Gross Margin55.87%
Net Profit Margin19.66%
Debt/Equity Ratio0%

How did IRLAB A perform over the long term?

See historical performance and comparison